+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Sodium Dependent Glucose Co Transporter 2"

From
Diabetes Drugs - Global Strategic Business Report - Product Thumbnail Image

Diabetes Drugs - Global Strategic Business Report

  • Report
  • June 2026
  • 478 Pages
  • Global
From
From
From
DPP-IV Inhibitors - Global Strategic Business Report - Product Thumbnail Image

DPP-IV Inhibitors - Global Strategic Business Report

  • Report
  • June 2026
  • 82 Pages
  • Global
From
From
From
From
From
From
From
From
From
Type 2 Diabetes - Pipeline Insight, 2026 - Product Thumbnail Image

Type 2 Diabetes - Pipeline Insight, 2026

  • Drug Pipelines
  • April 2026
  • 280 Pages
  • Global
From
From
From
From
Type 2 Diabetes Market 2026-2030 - Product Thumbnail Image

Type 2 Diabetes Market 2026-2030

  • Report
  • April 2026
  • 305 Pages
  • Global
From
Non-Insulin Diabetes Therapeutics Market 2026-2030 - Product Thumbnail Image

Non-Insulin Diabetes Therapeutics Market 2026-2030

  • Report
  • January 2026
  • 286 Pages
  • Global
From
From
Loading Indicator

The Sodium Dependent Glucose Co Transporter 2 (SGLT2) market is a subset of the Endocrine and Metabolic Disorders Drugs market. SGLT2 inhibitors are a class of drugs used to treat type 2 diabetes, a chronic condition in which the body does not produce enough insulin or is unable to use insulin effectively. These drugs work by blocking the reabsorption of glucose in the kidneys, allowing it to be excreted in the urine. This helps to reduce blood glucose levels and improve glycemic control. The SGLT2 market is highly competitive, with several major pharmaceutical companies offering products. These include AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen Pharmaceuticals, Merck, Novo Nordisk, and Sanofi. Each company offers a range of products, including both branded and generic versions. Show Less Read more